News|Videos|October 7, 2025

Lawrence Eichenfield, MD; and Rocco Serrao, MD, react to roflumilast approval for pediatric atopic dermatitis

Author(s)Lawrence Eichenfield, MD, Rocco Serrao, MD

Fact checked by: Joshua Fitch, Senior Editor

A pair of roflumilast clinical trial investigators react to the FDA approval of the 0.05% formulation to treat atopic dermatitis in children aged 2 to 5 years.

A newly approved nonsteroidal topical agent offers pediatricians and caregivers an additional treatment option for young children with atopic dermatitis (AD). Lawrence Eichenfield, MD; and Rocco Serrao, MD, discussed the expanded indication of roflumilast 0.05% cream (Zoryve; Arcutis Biotherapeutics), a phosphodiesterase 4 inhibitor, for children aged 2 to 5 years with mild to moderate AD.